YAP异常激活导致肝细胞身份丧失:酒精性肝炎的关键机制
本研究探讨Hippo/YAP通路在酒精性肝炎中的作用。分析移植肝标本发现Hippo通路下调、YAP异常激活,体外和体内实验表明YAP过激活导致肝细胞胆管分化及再生功能丧失,而YAP抑制剂可恢复肝细胞成熟表型,提示靶向YAP是潜在治疗策略。
要点
- 酒精性肝炎肝细胞中Hippo通路下调、YAP异常激活。
- YAP过激活导致肝细胞去分化及再生能力受损。
- YAP抑制剂可恢复酒精性肝炎肝细胞成熟表型。
核心结论
- YAP异常激活通过导致肝细胞身份丧失和再生受损,在酒精性肝炎肝细胞转分化中起重要作用,靶向YAP是有前景的治疗策略。
研究设计与样本
- 研究分析因酒精性肝炎或酒精性肝硬化行肝移植的患者肝标本及对照肝,采用RNA-seq、实时PCR、western blot、免疫组化和激光显微切割后转录组分析。
- 体外转染组成性激活YAP(YAPS127A)的原代人肝细胞,并用YAP抑制剂处理HepaRG细胞和来自酒精性肝炎肝的原代人肝细胞。
- 使用乙醇暴露(Lieber de Carli)和四氯化碳诱导肝再生的小鼠模型,在肝细胞转导YAPS127A后进行观察。
主要发现
- 酒精性肝炎样本中,全肝和显微切割肝细胞的RNA-seq及免疫组化显示Hippo通路显著下调,表现为活性MST1激酶水平降低和肝细胞YAP异常激活。
- 体外和体内肝细胞YAP过激活导致胆管分化和再生能力等关键生物学功能丧失。
- YAP抑制剂可恢复来自酒精性肝炎患者的异常肝细胞的成熟肝细胞表型。
- 乙醇喂养小鼠中,YAPS127A激活YAP导致肝细胞分化丧失。
- 四氯化碳中毒后,YAPS127A阻碍肝细胞增殖。
临床怎么用
- 靶向YAP可能成为酒精性肝炎的治疗策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alcoholic hepatitis (AH) is a life-threatening disease with limited therapeutic options, as the molecular mechanisms leading to death are not well understood. This study evaluates the Hippo/Yes-associated protein (YAP) pathway which has been shown to play a role in liver regeneration. METHOD: The Hippo/YAP pathway was dissected in explants of patients transplanted for AH or alcohol-related cirrhosis and in control livers, using RNA-seq, real-time PCR, western blot, immunohistochemistry and transcriptome analysis after laser microdissection. We transfected primary human hepatocytes with constitutively active YAP (YAPS127A) and treated HepaRG cells and primary hepatocytes isolated from AH livers with a YAP inhibitor. We also used mouse models of ethanol exposure (Lieber de Carli) and liver regeneration (carbon tetrachloride) after hepatocyte transduction of YAPS127A. RESULTS: In AH samples, RNA-seq analysis and immunohistochemistry of total liver and microdissected hepatocytes revealed marked downregulation of the Hippo pathway, demonstrated by lower levels of active MST1 kinase and abnormal activation of YAP in hepatocytes. Overactivation of YAP in hepatocytes in vitro and in vivo led to biliary differentiation and loss of key biological functions such as regeneration capacity. Conversely, a YAP inhibitor restored the mature hepatocyte phenotype in abnormal hepatocytes taken from patients with AH. In ethanol-fed mice, YAP activation using YAPS127A resulted in a loss of hepatocyte differentiation. Hepatocyte proliferation was hampered by YAPS127A after carbon tetrachloride intoxication. CONCLUSION: Aberrant activation of YAP plays an important role in hepatocyte transdifferentiation in AH, through a loss of hepatocyte identity and impaired regeneration. Thus, targeting YAP is a promising strategy for the treatment of patients with AH. LAY SUMMARY: Alcoholic hepatitis is characterized by inflammation and a life-threatening alteration of liver regeneration, although the mechanisms behind this have not been identified. Herein, we show that liver samples from patients with alcoholic hepatitis are characterized by profound deregulation of the Hippo/YAP pathway with uncontrolled activation of YAP in hepatocytes. We used human cell and mouse models to show that inhibition of YAP reverts this hepatocyte defect and could be a novel therapeutic strategy for alcoholic hepatitis.
引用
- Bou Saleh M, Louvet A, Ntandja-Wandji LC, et al. Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis. J Hepatol. 2021. PMID: 34129887. doi:10.1016/j.jhep.2021.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。